Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ikena Oncology, Inc. IKNA
$7.04
-$0.19 (-2.76%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
258388125.00000000
-
week52high
7.64
-
week52low
1.94
-
Revenue
15618000
-
P/E TTM
-4
-
Beta
0.74515100
-
EPS
-2.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | Outperform | 13 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 13 апр 2022 г. |
| HC Wainwright & Co. | Buy | 23 дек 2021 г. | |
| Credit Suisse | Outperform | Outperform | 13 авг 2021 г. |
| William Blair | Outperform | 20 апр 2021 г. | |
| Credit Suisse | Outperform | Outperform | 08 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 29 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 29 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Manfredi Mark | A | 220000 | 220000 | 03 янв 2023 г. |
| Marango Jotin | A | 105000 | 105000 | 03 янв 2023 г. |
| Zhang Xiaoyan Michelle | A | 105000 | 105000 | 03 янв 2023 г. |
| Ecsedy Jeffrey | A | 105000 | 105000 | 03 янв 2023 г. |
| Santillana Sergio L. | A | 105000 | 105000 | 03 янв 2023 г. |
| Hughes Owen | A | 35040 | 35040 | 15 дек 2022 г. |
| ORBIMED ADVISORS LLC | D | 2098097 | 96035 | 24 июн 2022 г. |
| ORBIMED ADVISORS LLC | D | 2002062 | 65965 | 24 июн 2022 г. |
| Bonita David P | D | 2098097 | 96035 | 24 июн 2022 г. |
| Bonita David P | D | 2002062 | 65965 | 24 июн 2022 г. |
Новостная лента
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
07 ноя 2022 г. в 11:30
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
GlobeNewsWire
05 окт 2022 г. в 08:05
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, IK-175, will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held in-person in Boston, MA and virtually on November 8-12, 2022.
Ikena Oncology to Participate in Spring 2022 Investor Conferences
GlobeNewsWire
18 мая 2022 г. в 07:00
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
12 мая 2022 г. в 09:47
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season?
Zacks Investment Research
11 мая 2022 г. в 09:47
Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.